Company Overview and News


Add ANR
to your dashboard

Headline News

Anatara Lifesciences to reveal details on animal health company

2017-08-17 proactiveinvestors.com.au
Anatara Lifesciences Ltd (ASX:ANR) has been granted a trading halt by the ASX, pending the Evaluation and License Option Agreement with animal health company Zoetis Inc. for Detach™.

Appointment of Chairman

2017-04-20 londonstockexchange
Redx Pharma, the research and development company focused on cancer, immunology and infection, announces that it has appointed Mr Iain Ross as Chairman of its Board of Directors and as a Non-Executive Director of the Company, effective from 1st May 2017.

Global Market for Breakthrough Therapy Designation Drugs Should Reach $99.2 Billion by 2022 from $48.8 Billion in 2017 at a CAGR of 15.2% - Research and Markets

2017-02-20 prnewswire
Research and Markets has announced the addition of the "Breakthrough Therapies: Market Dynamics and Investment Opportunities" report to their offering.

Anatara Lifesciences Ltd product moves a step closer to market

2016-10-04 proactiveinvestors.com.au
Anatara Lifesciences Ltd (ASX:ANR) has achieved a significant milestone through submission of its application to register ‘Detach’ for commercial marketing in Australia. Detach is a natural, non-antibiotic alternative for the control of diarrhoea in piglets. Once the application has been approved by the Australian Pesticides and Veterinary Medicines Authority, a marketing authorisation or registration will be issued.

Anatara Lifesciences Ltd's Dr Paul Schober outlines Detach™ at Spotlight CEO Session

2016-08-05 proactiveinvestors.com.au
Anatara Lifesciences Ltd (ASX:ANR) is developing therapeutics for gastrointestinal diseases such in pigs and humans. Its lead product Detach™ is a natural therapy that prevents and treats gastrointestinal diseases, with the company on track to lodge regulatory approvals, with its Australian launch planned for 2017. This week Dr Paul Schober, CEO, joined the Proactive Spotlight CEO Investor Session in Sydney, outlining the company strategy to investors.

Proactive Spotlight CEO Sessions: Gain Access to August Presentations

2016-08-04 proactiveinvestors.com.au
The Proactive's Spotlight CEO Sessions exclusively featured Medical Cannabis, Agriculture, Biotech and Industrial in Sydney this week.

Proactive Spotlight CEO Investor Sessions: Cellmid, Anatara, Hazer, Zelda Therapeutics, Real Estate Investar

2016-07-25 proactiveinvestors.com.au
Proactive Investors is delighted to invite you to attend Proactive's Spotlight CEO Investor Session in Sydney on Wednesday 3rd August 2016. It promises to be another fascinating Investor Session. Registrations are already filling up, so you better be quick. REGISTER HERE: Wednesday, 3rd August

Proactive Spotlight CEO Investor Sessions: Cellmid, Anatara, Hazer, Zelda Therapeutics

2016-07-21 proactiveinvestors.com.au
Proactive Investors is delighted to invite you to attend Proactive's Spotlight CEO Investor Session in Sydney on Wednesday 3rd August 2016. It promises to be another fascinating Investor Session. Registrations are already filling up, so you better be quick. REGISTER HERE: Wednesday, 3rd August

Anatara Lifesciences Ltd to detail Detach™ at CEO Spotlight Session

2016-07-21 proactiveinvestors.com.au
Anatara Lifesciences Ltd (ASX:ANR) is developing therapeutics for gastrointestinal diseases such in pigs and humans. Its lead product Detach™ is a natural therapy that prevents and treats gastrointestinal diseases, with the company on track to lodge regulatory approvals, with its Australian launch planned for 2017. Furthermore, unlike antibiotics, Detach™ will not contribute to antimicrobial resistance.

Can PINEAPPLE win the war against superbugs? | Daily Mail Online

2016-06-25 dailymail.co.uk
But now scientists believe enzymes found in the stems and roots of the fruit could help in the war against drug-resistant superbugs.

Pineapples could play key role in global superbug battle

2016-06-23 smh.com.au
Enzymes found in pineapple stems and roots could prove key to developing alternatives to antibiotics. Photo: Eddie Jim

Anatara Lifesciences Ltd delves further into treatment of diarrhoea in pigs

2016-06-16 proactiveinvestors.com.au
Anatara Lifesciences Ltd (ASX:ANR) has commenced a third field trial to win local registration for Detach, to prevent and treat the incidence of scour (diarrhoea) in pigs. Anatara’s third Australian field trial is being conducted on a major commercial piggery by enrolling 450 two-day old unweaned piglets. The objective of this study is to provide detailed safety data on Detach when administered orally to piglets at dose rates higher than the recommended single dose.

Appendix 4C - quarterly

2016-04-14 asx.com.au

Diarrhea Pipeline Market Research Report H1 2016

2016-04-01 prnewswire
New market research report titled, "Diarrhea - Pipeline Review, H1 2016," provides an overview on therapeutic pipeline of Diarrhea while helping enhance decision making capabilities and create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Milestone and Market Update

2016-04-01 asx.com.au

Appendix 3B

2016-03-14 asx.com.au

Half Yearly Report and Accounts

2016-02-23 asx.com.au

Zoetis (ZTS) Juan Ramón Alaix on Q4 2015 Results - Earnings Call Transcript

2016-02-16 seekingalpha
Zoetis, Inc. (NYSE:ZTS)Q4 2015 Earnings CallFebruary 16, 2016 8:30 am ETExecutivesJohn O'Connor - Vice President, Investor RelationsJuan Ramón Alaix - Chief Exe

Appendix 4C - quarterly

2016-01-27 asx.com.au

Appendix 3B

2016-01-11 asx.com.au

Appendix 3B

2015-11-17 asx.com.au